Projekt
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention (ARISE-Study)
Automatisch geschlossen · 2015 bis 2017
Flügel Dominique, Zieglgänsberger Dominik, Müller Anna
Art
Klinische Forschung
Reichweite
Multizentrisch, KSSG als teilnehmendes Zentrum
Bereiche
Status
Automatisch geschlossen
Start
2015
Ende
2017
Finanzierungsart
Industrie
Studiendesign
Phase 3, multicenter, randomized, stratified, double-blind, placebo-controlled,
parallel-group study of subjects with episodic migraine. Approximately 540 subjects will be
randomized 1:1 to placebo or AMG 334 70 mg. The randomization will be stratified by region
(North America vs Other) and prior treatment with migraine prophylactic medication
(prior migraine prophylactic medication treatment vs no prior migraine prophylactic medication
treatment).
Schlagwörter (Tags)
episodic migraine, cgrp-receptor-antagonist
Webseite
Projektpartner
Quintiles
Kurzbeschreibung/Zielsetzung
To evaluate the effect of AMG 334 compared to placebo on the change from baseline in monthly migraine days, in subjects with episodic migraine